Professor Leon Aarons (BSc, MSc, PhD) - publications

2012

• Kayode Ogungbenro and Leon Aarons. (2012). A semi-mechanistic gastric emptying pharmacokinetic model for 13C-octanoic acid: An evaluation using simulation. European Journal of Pharmaceutical Science, 45, 302-310. eScholarID:161187
• Graham H, Walker M, Jones O, Galetin A and Aarons L. (2012). Comparison of in vivo and in silico methods used for prediction of tissue:plasma partition coefficients in rat. J Pharm Pharmacol, 64(3), 383-396. eScholarID:159146
• Kerenaftali Klein, Ivelina Gueorguieva and Leon Aarons. (2012). Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9. J Pharmacokinet Pharmacodyn, 39, 147-160. eScholarID:161189
• SY Amy Cheung, Oneeb Majid, James WT Yates and Leon Aarons. (2012). Structural identifiability analysis and reparameterisation (parameter reduction) of a cardiovascular feedback model. European Journal of Pharmaceutical Science, 46, 259-271. eScholarID:161188

2011

• Kayode Ogungbenro, Lakshmi Vasist, Robert Maclaren, George Dukes, Malcolm Young and Leon Aarons. (2011). A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orall administered acetaminophen in critically ill patients. Pharm Res, 28, 394-404. eScholarID:112723 | DOI:10.1007/s11095-010-0290-8
• Helen Graham, Mike Walker, Owen Jones, James Yates, Aleksandra Galetin and Leon Aarons. (2011). Comparison of in-vivo and in-silico methods used for prediction of tissue: plasma partition coefficients in rat. Journal of Pharmacy and Pharmacology, 64, 383-396. eScholarID:161183
• I Perogamvros, L Aarons, AG Miller, PJ Trainer and DW Ray. (2011). Corticosteroid-binding globulin regulates cortisol pharmacokinetics. Clinical Endocrinology, 74, 30-36. eScholarID:119107 | DOI:10.1111/j.1365-2265.2010.03897.x
• Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. (2011). Critique of the two-fold measure of prediction success for ratios:application for the assessment of drug-drug interactions. Drug Metab Dispos, 39(2), 170-173. eScholarID:95952 | DOI:10.1124/dmd.110.036103
• S.J. Danson, P. Johnson, T.H. Ward, M. Dawson, O. Denneny, G. Dickinson, L.Aarons, A. Watson, D. Jowle, J. Cummings, L. Robson, G. Halbert, C. Dive, M.Ranson. (2011). Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Ann Oncol, 22(7), 1653-60. eScholarID:136661 | DOI:10.1093/annonc/mdq638
• Kayode Ogungbenro and Leon Aarons. (2011). Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments. J Pharmacokinet Pharmacodyn, 38, 449-469. eScholarID:133712 | DOI:10.1007/s10928-011-9203-7
• L Aarons, B Sadler, M Pitsiu, J Sjovall, J Henriksson and V Molnar. (2011). Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants and children. Brit J Anaesthesia, 107(3), 409-24. eScholarID:130464 | DOI:10.1093/bja/aer154
• L. Dickinson, M. Boffito, D. Back, L. Else, N. von Hentig, G. Davies, S. Khoo, A.Pozniak, G. Moyle, L. Aarons. (2011). Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies. Antimicrob. Agents Chemother, 107, 409-424. eScholarID:136660 | DOI:10.1128/AAC.00887-10
• Kayode Ogungbenro and Leon Aarons. (2011). Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid. J Pharmacokinet Pharmacodyn, 38, 279-292. eScholarID:136659 | DOI:10.1007/s10928-011-9193-5
• Steven Lane, Sameh-Al-Zubiedi, Ellen Hatch, Ivan Matthews, Andrea L Jorgensen, Panos Deloukas, Ann K Daly, B Kevin Park, Leon Aarons, Kayode Ogungbenro, Farhad Kamali, Dyfrig Hughes and Munir Pirmohamed. (2011). The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. British Journal of Clinical Pharmacology, 73(1), 66-76. eScholarID:161185

2010

• Graham H, Yates J, Galetin A and Aarons L. (2010). Development of a novel method for updating the predicted partition coefficient values generated by an existing in silico prediction method. Presented at PKUK meeting. Bristol. eScholarID:107116
• Eunice Yuen, Ivelina Gueorguieva, Stephen Wise, Danny Soon, Leon Aarons. (2010). Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn, 37, 3-24. eScholarID:84355 | DOI:10.1007/s10928-009-9138-4
• James Galea, Kayode Ogungbenro, Sharon Hulme, Andrew Greenhalgh, Leon Aarons, Sylvia Scarth, Peter Hutchinson, Samantha Grainger, Andrew King, Stephen J Hopkins, Nancy Rothwell and Pippa Tyrell. (2010). Intravenous anakinra can achieve experimentally effective concentrations in the central nervous systemwithin a therapeutic time window: results of a dose-ranging study. Journal of Cerebral Blood Flow & Metabolism, 00, 1-9. eScholarID:112719
• L.Aarons and K.Ogungbenro. (2010). Optimal Design of Pharmacokinetic Studies. Basic & Clinical Pharmacology & Toxicology, 106, 250-255. eScholarID:83411 | DOI:10.1111/j.1742-7843.2009.00533.x
• K Ogungbenro, R MacLaren, G Dukes, M Young, L Aarons, LS Vasist. (2010). Population Pharmacokinetic Modeling of Acetaminophen (APAP), A Surrogate for Gastric Emptying, in Critically Ill Patients Tolerant And Intolerant To Enteral Nutrition. Clinical Pharmacology and Therapeutics, 87, S1-S7. eScholarID:83406
• K.Ogungbenro, L.Aarons. (2010). Sample Size/Power Calculations for Repeated Ordinal Measurements in Population Pharmacodynamic Experiments. Journal of Pharmacokinetic and Pharmacodynamics, 37(1), 67-83. eScholarID:83408 | DOI:10.1007/s10928-009-9144-6
• Kayode Ogungbenro and Leon Aarons. (2010). Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements. Journal of Biopharmaceutical Statistics, 20, 1026-1042. eScholarID:112726 | DOI:10.1080/10543401003619205
• Kayode Ogungbenro and Leon Aarons. (2010). Sample-size calculations for multi-group comparison in population pharmacokinetic experiments. Pharmaceutical Statistics, 9, 255-268. eScholarID:112722 | DOI:10.1002/pst.388

2009

• Kayode Ogungbenro, Leon Aarons. (2009). An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments. Journal of Biopharm Statistics, 19, 174-189. eScholarID:43603 | DOI:10.1080/10543400802536131
• K.Ogungbenro, A.Dokoumetzidis, L.Aarons. (2009). Application of Optimal Design Methodologies in Clinical Pharmacology Experiments. Pharmaceutical Statistics, 8(3), 239-252. eScholarID:83414 | DOI:10.1002/pst.354
• Ogungbenro K, Dokoumetzidis A and Aarons L. (2009). Application of optimal design methodologies in clinical pharmacology experiments. Pharmaceutical Statistics, 8, 239-252. eScholarID:79996 | DOI:10.1002/pst.354
• Graham H, Jones O, Galetin A and Aarons L. (2009). Comparison of in vivo and in silico methods to predict tissue:plasma partition coefficients in rat. Presented at PKUK meeting. Birmingham. eScholarID:107127
• Emma Dean, Duncan Jodrell, Kate Connolly, Sarah Dobson, Jacques Jolivet, Jon Durkin, Stephen Morris, Debra Jowle, Tim Ward, Jeff Cummings, Gemma Dickinson, Aarons, L, Eric LaCasse, Lesley Robson, Dive, C, Malcolm Ranson. (2009). Phase I trial of AEG35156 Administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. Journal of Clinical Oncology, 27, 1-9. eScholarID:1d18768 | DOI:10.1200/JCO.2008.19.5677
• K.Ogungbenro, I.Matthews, M.Looby, G.Kaiser, G.Graham, L.Aarons. (2009). Population Pharmacokinetics and Optimal Design of Paediatric Studies for Famciclovir. British Journal of Clinical Pharmacology, 68(4), 546-560. eScholarID:83413 | DOI:10.1111/j.1365-2125.2009.03479.x
• L Dickinson, M Boffito, D Back, L Waters, L Else, G Davies, S Khoo, A Pozniak and L Aarons. (2009). Population pharmacokinetics of ritonavir-boosted atazanabir in HIV-infected patients and healthy volunteers. J Antimicrobial Chemotherapy, 63, 1233-1243. eScholarID:83404 | DOI:10.1093/jac/dkp102
• Dokoumetzidis A, Aarons L. (2009). Proper lumping in systems biology models. IET Systems Biology, 3, 40-51. eScholarID:1d18756 | DOI:10.1049/iet-syb:20070055

2008

• Aristides Dokoumetzidis, Leon Aarons. (2008). Analytical expressions for combining population pharmacokinetic parameters from different studies. Journal of Biopharm Statis, 18, 662-676. eScholarID:43224 | DOI:10.1080/10543400802071360
• Marylore Chenel, Francois Bouzom, Aarons L, Ogungbenro K. (2008). Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse design using PopDes. J Pharmacokinet Pharmacodyn, 35, 635-659. eScholarID:1d18457 | DOI:10.1007/s10928-008-9104-6
• Marylore Chenel, Francois Bouzom, Fanny Cazade, Ogungbenro K, Aarons L, France Mentre. (2008). Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam as a phase 1 compound. Part 2: clinial trial results. J Pharmacokinet Pharmacodyn, 35, 661-681. eScholarID:1d18459 | DOI:10.1007/s10928-008-9105-5
• Kayode Ogungbenro, Leon Aarons. (2008). How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach. Eur J Clin Pharmacol, 64, 705-713. eScholarID:43722 | DOI:10.1007/s00228-008-0493-7
• Ogungbenro K, Gordon Graham, Ivelina Gueorguieva, Aarons L. (2008). Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments. Journal of Biopharmaceutical Statistics, 18, 342-358. eScholarID:1d17042 | DOI:10.1080/10543400701697208
• Kayode Ogungbenro, Leon Aarons. (2008). Optimisation of sampling windows design for population pharmacokinetic experiments. J Pharmacokinet Pharmacodyn, 35, 465-482. eScholarID:43380 | DOI:10.1007/s10928-008-9097-1
• Laura Dickinson, Marta Boffito, Saye H Khoo, Malte Schutz, Aarons L, Anton L Pozniak, David J Back. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Journal of Antimicrobial Chemotherapy, 62, 161-167. eScholarID:1d18462 | DOI:10.1093/jac/dkn187
• Laura Dickinson, Marta Boffito, David J Back, Saye H Khoo, Anton L Pozniak, Peter Mugyenyi, Concepta Merry, Reshma Saskia Autar, David M Burger, Aarons, L. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 62, 1344-1355. eScholarID:1d18461 | DOI:10.1093/jac/dkn399
• Ogungbenro K, Aarons L. (2008). Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations. J of Biopharm Statistics, 18, eScholarID:1d18460 | DOI:10.1080/105400802375845

2007

• Dokoumetzidis A, Aarons L. (2007). Bayesian optimal designs for pharmacokinetic models: Sensitivity to uncertainty. Journal of Biopharmaceutical Statistics, 17, 851-867. eScholarID:1d16165
• Ogungbenro K, Aarons L. (2007). Design of population pharmacokinetic experiments using prior information. Xenobiotica, 37(10), 1311-1330. eScholarID:1d17025
• Grant Langdon, Ivelina Gueorguieva, Aarons L, Mats Karlsson. (2007). Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM. Eur J Clin Pharmacol, 63, 485-498. eScholarID:1d16091
• Ruth Ledder, Gilbert P, Sharon A Huws, Aarons L, Martin P Ashley, Peter S Hull, McBain AJ. (2007). Molecular Analysis for the Subgingival Microbiota in Health and Disease. Applied and Environmental Microbiology, 73:2, 516-523. eScholarID:1d15340
• Ogungbenro K, Ivelina Gueorguieva, Oneeb Majid, Gordon Graham, Aarons L. (2007). Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs. Journal of Pharmacokinetics and Pharmacodynamics, 34(3), 313-331. eScholarID:1d16093

2006

• Ivelina Gueorguieva, Aarons L, Rowland M. (2006). Diazepam pharmacokinetics from preclinical to Phase 1 using a Bayesian Population physiologically based pharmacokinetics model with informative prior distributions in Winbugs. Journal of Pharmacokinetics and Pharmacodynamics, 33, 571-594. eScholarID:1d14355 | DOI:10.1007/s10928-006-9023-3
• Ivelina Gueorguieva, Aarons L, Ogungbenro K, Karin M Jorga, Rodgers TA, Rowland M. (2006). Optimal design for multivariate response pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics, 33, 97-124. eScholarID:1d13343
• Gordon Graham, Aarons L. (2006). Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments. Statistics in Medicine, 25, 4004-4019. eScholarID:1d14352
• Wang Ning ShangGuan, QingQuan Lian, Aarons L, Ivan Matthews, ZengShou Wang, XiaLin Chen, Nick Freemantle, Fang Gao Smith. (2006). Pharmacokinetics of a single bolus of propofol in chinese children of different ages. Anesthesiology, 104, 27-32. eScholarID:1d13435
• Julie A Simpson, Dyfrig Hughes, Christine Manyando, Kalifa Bojang, Aarons L, Peter Winstanley, Geoffrey Edwards, William A Watkins, Steve Ward. (2006). Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. British Journal of Clinical Pharmacology, 61(3), 289-300. eScholarID:1d12739 | DOI:10.1111/j.1365-2125.2005.02567.x
• Dokoumetzidis A, Aarons L. (2006). Propagation of Population PK and PD Information using a Bayesian Approach: Dealing with Non-Exchangeability. Journal of Pharmacokinetics and Pharmacodynamics, 33, 29-48. eScholarID:1d13418
• Ogungbenro K, Aarons L, Gordon Graham. (2006). Sample size calculations based on generalised estimating equations for population pharmacokinetic experiments. Journal of Biopharmaceutical Studies, 16, 135-150. eScholarID:1d12753
• Geraint R Davies, Richard Brindle, Saye H Khoo, Aarons L. (2006). Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrobial Agents and Chemotherapy, 50(9), 3154-3156. eScholarID:1d13651 | DOI:10.1128/AAC.00774-05

2005

• Lynne Evans, Aarons L, Chris Brearley. (2005). A Pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase 1 studies. Journal of Pharmacy and Pharmacology, 57, 183-189. eScholarID:1d9827
• Aarons L, Ikhlas Ali Ahmed, Dirk Deleu. (2005). Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. Archives of Medical Research, 36, 49-53. eScholarID:1d10415
• Iva Gueorguieva, Ivan A Nestorov, Aarons L, Rowland M. Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan, Pharmaceutical Research. Vol. 22. 2005. 1614-1626.
• Ferdinand Rombout, Aarons, L, Mats Karlsson, Anthony Man, France Mentre, Peter Nygren, Amy Racine, Hans Schaefer, Jean-Louis Steimer, Inaki Troconiz, Achiel van Peer. (2005). Modelling and simulation in the development and use of anti-cancer agents: an underused tool? Journal of Pharmacokinetics and Pharmacodynamics, 31(6), 419-440. eScholarID:1d11172
• Marylore Chenel, Ogungbenro K, Vincent Duval, Christian Laveille, Roeline Jochemsen, Aarons L. (2005). Optimal blood sampling time windows for parameter estimation using a population approach: design of a Phase II Clinical Trial. Journal of Pharmacokinetics and Pharmacodynamics, 32, 737-756. eScholarID:1d13346
• Tony Whitehouse, Jorge A Cepeda, Rob Shulman, Aarons, L, Ricardo Nalda-Molina, Caroline Tobin, Alasdair MacGowan, Steve Shaw, Chris Kibbler, Mervyn Singer, A Peter R Wilson. (2005). Pharmacokinetic studies in linezolid and teicoplanin in the crtically ill. Journal of Antimicrobial Chemistry, 55, 333-340. eScholarID:1d10430
• Dokoumetzidis A, Aarons L. (2005). Propagation of population pharmacokinetic information using a bayesian approach: comparison with meta-analysis. Journal of Pharmacokinetics and Pharmacodynamics, 32, 401-418. eScholarID:1d12740
• Eva Parker, Aarons L, Rowland M, Guillemette Resplandy. (2005). The pharmacokinetics of perindoprilat in normal volunteers and patients: Influence of age and disease state. European Journal of Pharmaceutical Sciences, 26, 104-113. eScholarID:1d11088
• Ogungbenro K, Gordon Graham, Ivelina Gueorguieva, Aarons L. (2005). The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments. Computer Methods and Programs in Biomedicine, 80, 115-125. eScholarID:1d11645

2004

• Aarons L, Baxter C, Gupta S. (2004). Pharmacodynamics of Controlled Released Verapamil in Patients with Hypertension: An Analysis using Spline Functions. Biopharmaceutics & Drug Disposition, 25, 219-225. eScholarID:1d25849
• Callies S, Dinesh P de Alwis, Atul Mehta, Michael Burgess, Aarons L. (2004). Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuqidar.3HCI (LY335979). Cancer Chemother Pharmacol, 54, 39-48. eScholarID:1d8989
• Pitsiu M, Hussein Ziad, Majid Oneeb, Aarons L, Longueville Mark de, Stockis Armel. (2004). Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. British Journal Of Clinical Pharmacology, 57:4, 402-411. eScholarID:1d25762
• Ziad Hussein, Maria Pitsiu, Oneeb Majid, Aarons L, Marc de Longueville, Armel Stockis. (2004). Retrospective population pharmacokinetics of levocetrizine in atopic children receiving cetirizine: the ETAC study. Br J Clin Pharmacol, 59, 28-37. eScholarID:1d9080

2003

• Pitsiu M, Parker E. M, Aarons L, Rowland M. (2003). A Bayesian Method Based on Clotting Factor Activity for the Prediction of Maintenance Warfarin Dosage Regimens. Therapeutic Drug Monitoring, 25, 36 - 40. eScholarID:1d4319
• CalliesS, de AlwisD.P, WrightJ.G, SandlerA, BurgessM, Aarons L. (2003). A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Chemotherapy Phamacology, 51, 107 - 118. eScholarID:1d6764
• Callies S, de Alwis D.P, Harris A, Vasey P, Beijnen J.H, Schellens J.H, Burgess M, Aarons L. (2003). A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). British Journal Of Clinical Pharmacology, 56, 46-56. eScholarID:1d25115
• Mithwani S, Aarons L, O Kokwaro G.O, Majid O, Muchohi S, Edwards G, Mohamed S, Marsh K, Watkins W. (2003). Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. British Journal Of Clinical Pharmacology, 57(2), 146-152. eScholarID:1d25761
• MengovG, HadjitodorovSt, Aarons L. (2003). Prediction of serum tobramycin in patients with NONMEM and simulated annealing. Comptes Rendus de l'Academie Bulgare des Sciences, 56, 47 - 50. eScholarID:1d6765

2002

• Graham G, Gupta S, Aarons L. (2002). Determination of an Optimal Dosage Regimen using a Bayesian Decision Analysis of Efficacy and Adverse Effect Data. Journal of Pharmacokinetics Pharmacodynamics, 29, 67-88. eScholarID:1d1948
• Aarons L. (2002). Mixed effects modelling of toxicokinetic data. The Toxicologist, 66 (1-S), Abst. 862. eScholarID:17d63
• Gupta S, Modi N.B, Sathyan G, Ho P-L, Aarons L. (2002). Pharmacokinetics of Controlled-Release Verapamil in Healthy Volunteers and Patients with Hypertension or Angina. Biopharm. Drug Dispos, 23, 17-31. eScholarID:1d1118
• Simpson J.A, Aarons L, Collins W.E, Jeffery G.M, White N.J. (2002). Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology, 124, 247-263. eScholarID:1d1148
• Deleu D, Aarons L, Ahmed I.A. (2002). Study of the phamacokinetic profile of anti-epileptic drugs in an adult Omani epileptic population using NONMEM. Epilepsia, 43, 144. eScholarID:17d83

2001

• Evans N.D, Godfrey K.R, Chapman M.J, Chappell M.J, Aarons L, Duffell S.B. (2001). An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. J. Pharmacokin. Pharmacodyn, 28, 93-105. eScholarID:1d1081
• Aarons L, Balant L, Boobis A. (2001). COST B15: modelling in drug development. Br. J. Clin. Pharmacol, 13, 118-119. eScholarID:1d23209
• Nestorov I, Graham G, Duffell S, Aarons L, Fuseau E, Coates P. (2001). Computer-assisted clinical trial simulation: a phase II case study with naraptriptan. Pharmacol. Toxicol, 89 (suppl. 1), 17-18. eScholarID:1d1087
• Simpson J.A, Aarons L, White N.J. (2001). How can we do pharmacokinetic studies in the tropics? Trans. R. Soc. Trop. Med. Hyg, 95, 347-351. eScholarID:1d23210
• Aarons L, Graham G. (2001). Methodological approaches to the population analysis of toxicity data. Tox. Letts, 120, 405-410. eScholarID:1d23207
• Nestorov I, Graham G, Duffull S, Aarons L, Fuseau E, Coates P. (2001). Modeling and simulation for clinical trial design involving a categorical response: A phase II case study with naratriptan. Pharm. Res, 18, 1210-1219. eScholarID:1d23226
• Deleu D, Aarons L, Ahmed I. (2001). Population pharmacokinetics of free-carbamazepine in adult Omani epileptic patients. European Journal Of Clinical Pharmacology, 57, 243-248. eScholarID:1d23208
• Aarons L, Karlsson M.O, Mentre F, Rombout F, Steimer J-L, Peer A.v. (2001). Role of modelling and simulation in Phase I drug development. Eur. J. Pharm. Sci, 13, 115-122. eScholarID:1d1084

2000

• Duffull S.B, Chabaud S, Nony P, Laveille C, Girard P, Aarons L. (2000). A pharmacokinetic simulation model for ivabradine in healthy volunteers. Eur. J. Pharm. Sci, 10, 285-294. eScholarID:1d947
• Duffull S.B, Aarons L. (2000). Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. Clin. Pharmacol. Ther, 10, 275-284. eScholarID:1d946
• Simpson J.A, Watkins E.R, Price R.N, Aarons L, Kyle D.E, White N.J. (2000). Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother, 44, 3414-3424. eScholarID:1d948
• Aarons L, Graham G. (2000). Methodological approaches to the population analysis of toxicity data. Tox. Letts, 120, 405-410. eScholarID:1d949
• Ingwersen S.H, Pedersen P.C, Groes L, Nielsen K.K, Aarons L. (2000). Population pharmacokinetics of tiagabine in epileptic patients on monotherapy. Eur. J. Pharm. Sci, 11, 247-254. eScholarID:1d32726

1999

• Aarons L. (1999). "Population modelling". In: Variability in Human Drug Response. Proceedings of the Esteve Foundation Symposium VIII. Excerpta Medica, Amsterdam, 239-249. eScholarID:1d802
• Wakefield J, Aarons L, Racine-Poon A. (1999). "The Bayesian approach to population pharmacokinetic/pharmacodynamic modeling". In: Case Studies in Bayesian Statistics (Vol IV), Lecture Notes in Statistics. Springer-Verlag, New York, 140, 205-265. eScholarID:1d801
• Nestorov I, Aarons L, Rowland M. (1999). A mechanistically based model for the relationship between the tissue distribution parameters and the lipophilicity of a homologous series of barbiturates in rats. eScholarID:2d563
• Evans L, Aarons L, Coates P. (1999). A pharmacokinetic model for tenidap in normal volunteers and rheumatoid arthritis patients. Pharm. Res, 16, 1608-1615. eScholarID:1d798
• Herrick A.L, Grennan D.M, Aarons L. (1999). Lack of interaction between methotrexate and penicillins. Rheumatology, 38, 284-285. eScholarID:1d797
• Aarons L. (1999). Pharmacokinetic and pharmacodynamic modelling in drug development. Stat. Methods Med. Res. (editorial), 8, 181-182. eScholarID:1d32725
• Simpson J.A, Price R, Kuile ter F, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, Looareesuwan S, Aarons L, White N.J. (1999). Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin. Pharmacol. Ther, 66, 472-478. eScholarID:1d799
• Gupta S.K, Sathyan G, Lindemulder E.A, Ho P.-L, Sheiner L.B, Aarons L. (1999). Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin. Pharmacol. Ther, 65, 672-684. eScholarID:1d795
• Aarons L. (1999). Software for population pharmacokinetics and pharmacodynamics. Clin. Pharmacokin, 36, 255-264. eScholarID:1d800
• Graham G, Aarons L, Gupta S.K. (1999). The analysis of categorical/count data. Eur. J. Pharm. Sci, 8(2), eScholarID:1d32714
• Niopas I, Toon S, Aarons L, Rowland M. (1999). The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. Eur. J. Clin. Pharmacol, 55, 399-404. eScholarID:1d796

1998

• Duffull S, Nestorov I, Aarons L. (1998). Computer Assisted Design of Phase II(b) Oral Dose Ranging Trial for Naratriptan - Results of a Pilot Study. Scientific Conference "Pharmacokinetics - UK", Manchester, UK. November 4-6, 1998. eScholarID:2d557
• Nestorov I, Aarons L, Arundel P.A, Rowland M. (1998). Lumping of whole-body physiologically based pharmacokinetic models. J. Pharmacokin. Biopharm, 26, 21-46. eScholarID:1d661
• Chou C.H, Aarons L, Rowland M. (1998). Optimal experimental design for precise estimation of the parameters of the axial dispersion model of hepatic elimination. J. Pharmacokin. Biopharm, 26, 595-615. eScholarID:1d739
• Aarons, L, Rowland, M, Khan, A., Taborelli, G., Ferrea, G., Tarantino, V., Fioredda, F., Rosina-Parenti, R., Cavenaghi, L., Borgonovi, M. (1998). Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children. Eur. J. Pharm. Sci, 6, 265-270. eScholarID:1d664
• Khyl L.E.B, Rasmussen S.N, Aarons L, Jensen S.B. (1998). Population pharmacokinetics of cyclosporine: influence of covariables and assessment of cyclosporine absorption in kidney, lung, heart and heart+lung transplanted patients. eScholarID:2d303
• de Alwis D.P, Aarons L, Palmer J.L. (1998). Population pharmacokinetics of ondansetron: a covariate analysis. Br. J. Clin. Pharmac, 46, 117-125. eScholarID:1d659
• Nestorov I, Aarons L, Rowland M. (1998). Quantitative structure-pharmacokinetics relationships II. Mechanistically based model for the relationship between the tissue distribution parameters and the lipophilicity of the compounds. J. Pharmacokin. Biopharm, 26 (5), 521-545. eScholarID:1d690
• Lunn D.J, Aarons L. (1998). The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis. J. Pharmacokin. Biopharm, 26, 47-74. eScholarID:1d650

1997

• Lunn D. J, Aarons L. (1997). Markov chain Monte Carlo techniques for studying interoccasion and intersubject variability: application to pharmacokinetic data. Appl. Statist, 46, 73-91. eScholarID:1d427
• Nestorov I.A, Aarons L, Rowland M. (1997). Physiologically-based pharmacokinetic modelling of a homologous series of barbiturates in the rat: A sensitivity analysis. J. Pharmacol. Biopharm, 25 (4), 413-449. eScholarID:1d425
• Imbimbo B.P, Klietmann W, Broccali G.P, Cesana M, Aarons L. (1997). Population pharmacokinetics of rufloxacin in patients with acute exacerbations of chronic brochitis. Eur. J. Pharm. Sci, 5, 37-42. eScholarID:1d426
• Aarons, L, Balant, L.P., Danhof, M., Gex-Fabry, M., Gundert-Remy, U.A., Karlsson, M.O., Mentre, F., Morselli, P.L., Rombout, F., Rowland, M, Steimer, J.L., Vozeh, S. (1997). The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose, Commission of the European Community, Luxembourg. eScholarID:4d22

1996

• Nestorov I, Blakey G.A, Arundel P.A, Aarons L, Rowland M. (1996). A physiologically-based pharmacokinetic model for the distribution of barbiturates in rats. AAPS Tenth Anniversary Meeting, 27-31 October 1996, Seattle, Washington. eScholarID:2d49
• Aarons L. (1996). Population approaches/sparse data analysis for human variability in kinetics and dynamics. Environ. Toxicol. Pharmacol, 2, 197-199. eScholarID:1d610
• Aarons L, Balant L.P, Mentre F, Morselli P.L, Rowland M, Steimer J-L, Vozeh S. (1996). Practical experience and issues in designing and performing population pharmacokinetic / pharmacodynamic studies. eScholarID:2d1161
• Vozeh S, Steimer J-L, Rowland M, Morselli P, Mentre F, Balant L.P, Aarons L. (1996). The use of population pharmacokinetics in drug development. Clin Pharmacokin, 30, 81-93. eScholarID:1d529